Today we’re joined by Ivan Kairatov, a biopharma expert with deep experience in drug development and the intricate dance between innovation, regulation, and market perception. We'll be dissecting the recent developments with Intellia Therapeutics, a pioneer in CRISPR gene editing. The company has
Within the intricate ecosystem of a tumor, cancer cells are far from acting alone; they are surrounded by a complex network of supporting cells that form the tumor microenvironment. Among these collaborators, cancer-associated fibroblasts (CAFs) have emerged as particularly influential players.
Biopharma expert Ivan Kairatov joins us today to discuss a paradigm shift in evaluating cutaneous chronic graft-versus-host disease (cGVHD), a severe complication of stem cell transplantation. Drawing from his work with an international NIH task force, he explains why current assessment standards
Sophisticated nanodelivery systems that respond to multiple biological cues are rapidly redefining the landscape of targeted therapeutics, offering a highly precise method for overcoming the formidable barriers presented by diseases like metastatic cancer. This review explores the evolution of
A faint tinge of pink swirling in the toilet bowl is an unmistakable alarm bell for most, signaling an urgent need for medical attention, but for millions, this critical warning sign of a potentially treatable cancer remains completely invisible. New research reveals a shocking reality: individuals
With us today is Ivan Kairatov, a biopharma expert with deep experience in research and development, to discuss the evolving story of Sarepta’s gene therapy, Elevidys. We’ll explore how new long-term data is reshaping the clinical conversation around the therapy’s effectiveness, the commercial
